Automate Your Wheel Strategy on ETNB
With Tiblio's Option Bot, you can configure your own wheel strategy including ETNB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ETNB
- Rev/Share 0.0001
- Book/Share 3.3046
- PB 2.8324
- Debt/Equity 0.0028
- CurrentRatio 15.1857
- ROIC -0.8267
- MktCap 1388162880.0
- FreeCF/Share -2.7818
- PFCF -3.1607
- PE -3.2824
- Debt/Assets 0.0024
- DivYield 0
- ROE -0.9448
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ETNB | Goldman | -- | Neutral | -- | $11 | March 14, 2025 |
| Initiation | ETNB | Citigroup | -- | Buy | -- | $25 | March 13, 2025 |
| Initiation | ETNB | Wolfe Research | -- | Outperform | -- | -- | Feb. 4, 2025 |
News
89bio: Promising As Pegozafermin Nears Phase 3 Readout
ETNB
Published: August 11, 2025 by: Seeking Alpha
Sentiment: Positive
Published: August 11, 2025 by: Seeking Alpha
Sentiment: Positive
Pegozafermin is ETNB's long-acting FGF21 analog. It's undergoing three Phase 3 trials. Two of those late-stage trials are for MASH (F2-F4), and the third is for severe hypertriglyceridemia. Also, ETNB's ENTRUST SHTG is fully enrolled, with potential topline data by 1Q 2026, which may enable a BLA filing shortly after that.
Read More
Is 89BIO (ETNB) Stock Outpacing Its Medical Peers This Year?
ETNB
Published: March 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: March 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how 89BIO (ETNB) and Eton Pharmaceuticals, Inc. (ETON) have performed compared to their sector so far this year.
Read More
About 89bio, Inc. (ETNB)
- IPO Date 2019-11-11
- Website https://www.89bio.com
- Industry Biotechnology
- CEO Rohan Palekar
- Employees 93
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.